Paul A. Meyers, MD

Paul A. Meyers, MD

Pediatric Oncologist

Titles

Chief, Pediatric Sarcoma Service; Vice Chair for Clinical Affairs

Clinical Expertise

Pediatric Oncology; Osteosarcoma; Ewing Sarcoma; Leukemias; Rhabdomyosarcoma and Other Soft Tissue Developmental Tumors of Childhood

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Meyers accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral.

Blue Cross Blue Shield

In New York State

Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:

  • Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
  • Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
  • The Empire Indemnity Plan provides limited coverage for our services.

Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.

In New Jersey

Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.

Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.

Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.

OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).

Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.

Outside New York State and New Jersey

Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.

CIGNA

Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.

  • If you are a New York State resident: Please ask your insurance if you need a one-time referral.
  • If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.

Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.

EmblemHealth (including GHI, HIP, ConnectiCare, and Vytra)

Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, and HMO plans as well as their Enhanced Care Prime Network, which supports Medicaid Managed Care and Child Health Plus and Medicare plans. Memorial Sloan Kettering is also in-network with the New York State Essential Emblem Health plan, which can be purchased on the insurance exchange. Emblem Health does not include us in any of its Medicare plans or in any of its Select Care network plans. You must bring a referral from your Emblem primary care doctor to your first appointment.

Empire Blue Cross Blue Shield Health Plus

Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.

Health Insurance Exchanges

We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We're here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.

HealthSmart

Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.

Humana

Memorial Sloan Kettering is a designated Center of Excellence by Humana.

Interlink Health Services

Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.

Lifetrac

Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.

MagnaCare

Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.

Medicaid

New York State Medicaid covers physician and hospital services at Memorial Sloan Kettering. Patients are responsible for co-payments.

We also have contractual relationships involving Medicaid Managed Care plans. MSK is an in-network provider with Medicaid NY Emblem Health (formerly known as HIP) and Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.

Medicare

Hospital and physician services at Memorial Sloan Kettering are covered by standard Medicare insurance. You are responsible for co-insurance and deductible costs. 

In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem Medicare Advantage Plans.

In New Jersey: Memorial Sloan Kettering’s  New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.

If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.

Multiplan/Beech Street/PHCS

Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.

Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.

Multiple Insurance Plans

If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.

MVP

Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.

New York State Employee Health Insurance Plan (Empire Plan)

Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.

Oscar

Memorial Sloan Kettering is in-network with Oscar's Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.

Other Coverage Options

We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:

  • AXA Assistance USA
  • Beech Street
  • Integrated Health Plans
  • National Health Administrators
  • National Preferred Provider Network
  • UnitedHealthcare's Cancer Resource Services
  • United Resource Network
  • Veterans Choice Program
Oxford

Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford's Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.

QualCare

Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.

Specialty Care Management

Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.

TRICARE

Hospital and physician services at Memorial Sloan Kettering are covered by TRICARE. You are responsible for co-insurance and deductible costs.

UnitedHealthcare

Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.

UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.

United does not include us in any of the plans you can buy through the insurance exchanges.

Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.

World Trade Center Health Program

Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.

Contact and Location

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Mount Sinai School of Medicine

Residencies

Pediatrics - Mount Sinai Hospital

Fellowships

Pediatrics - Cornell Medical Center; Pediatrics - Memorial Sloan Kettering Cancer Center

Board Certifications

Pediatrics; Pediatric Hematology-Oncology

I am a pediatric oncologist with extensive experience in the treatment of sarcomas in children and young adults. At Memorial Sloan Kettering, we treat more children and young adults with sarcoma than anywhere else in the country. I am proud to be part of a team that takes a comprehensive approach to develop a personalized regimen of care, with the goal of saving the lives of our young patients.

Many of our patients are adolescents and young adults, who are transitioning from childhood dependence on their parents to independent living. We help them maintain their independence in every way during their cancer care, while still ensuring that they have the emotional and practical support of their family members.

Many of the types of cancer that arise in young adults are quite rare, and very few oncologists have experience treating them. Some young adults have a form of cancer that is seen much more commonly in children and adolescents. The team with the greatest expertise in managing their specific disease may therefore be based in the Department of Pediatrics. At Memorial Sloan Kettering, we believe that the most important service we provide to patients is a multidisciplinary healthcare team.

In addition to patient care, I direct clinical research aimed at developing and evaluating new therapies for sarcomas. I served for five years as Head of the Bone Sarcoma Strategy Group for the Children’s Cancer Group, where I directed national clinical trials for osteosarcoma and Ewing sarcoma. I have also conducted clinical trials at Memorial Sloan Kettering for the treatment of newly diagnosed and recurrent osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated sarcoma, and other unusual tumors that occur in children and young adults.

One area of study that I feel passionate about is the evaluation of muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), a promising drug for osteosarcoma which has been approved for use in Europe. It increases the ability of white blood cells to attack osteosarcoma tumor cells and to help the body to destroy the tumor.

Education is another important part of my role at Memorial Sloan Kettering. I serve as Vice Chair of Academic Affairs in the Department of Pediatrics. Memorial Sloan Kettering is proud to offer one of the most comprehensive training programs in pediatric hematology/oncology in the country. With a very large number of patients and a faculty with decades of experience, our trainees see an unparalleled variety of clinical challenges. Fellows also have the benefit of working with nearby institutions such as Weill Cornell Medical College and The Rockefeller University.

As a result of my patient care experience and research, I have authored or co-authored over 135 publications about sarcomas. In recognition of my work, I received the Willet E. Whitmore Award for Clinical Excellence from Memorial Sloan Kettering in 1995. I served as president of the Connective Tissue Oncology Society, a leading academic society devoted to the study of sarcomas. I am a member of the National Cancer Institute Physician Data Query Pediatric Board.

I am also the founding medical director for Happiness is Camping, a summer camp for children with cancer. I have had the extraordinary opportunity to help give these kids a respite from the rigors of cancer therapy and to see them blossom and thrive away from the hospital environment.

Awards and Honors

  • Castle Connolly: New York Magazine Top Doctors (2002-2018)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan Kettering experience and a literature review.. J Clin Oncol. 2001; 19 :870-880

Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK.. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.. Med Pediatr Oncol 2000; 35 :468-74

Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH, Ladanyi M.. Prognostic impact of INK4A deletion in Ewing sarcoma.. Cancer 2000; 89 :793-9

de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M.. Prognostic impact of P53 status in Ewing sarcoma.. Cancer 2000; 89 :783-92

Shamberger RC, Laquaglia MP, Krailo MD, Miser JS, Pritchard DJ, Gebhardt MC, Healey JH, Tarbell NJ, Fryer CJ, Meyers PA, Grier HE.. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.. J Thorac Cardiovasc Surg. 2000; 119 :1154-61

Saenz NC, Hass DJ, Meyers P, Wollner N, Gollamudi S, Bains M, LaQuaglia MP.. Pediatric chest wall Ewing sarcoma.. J Pediatr Surg. 2000; 35 :550-5

Guo W, Gorlick R, Ladanyi M, Meyers PA, Huvos AG, Bertino JR, Healey JH.. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop 1999; 365 :175-83

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA.. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 19 :2781-8

Flombaum CD, Meyers PA.. High-dose leucovorin as sole therapy for methotrexate toxicity.. J Clin Oncol 1999; 17 :1589-94

Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, Gorlick R.. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5 :621-7

Kushner BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers PA.. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.. J Clin Oncol 1998; 16 :3016-20

Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH.. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.. J Bone Joint Surg Am. 1998; 80 :1020-33

Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH.. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) protocol.. J Clin Oncol 1998; 16 :2452-8

Kawai A, Huvos AG, Meyers PA, Healey JH.. Osteosarcoma of the pelvis. Oncologic results of 40 patients.. Clin Orthop 1998; 348 :196-207

de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M.. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing sarcoma. J Clin Oncol 1998; 16 :1248-55

Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AG, Larson SM.. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AGThallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma, Larson SM.. Cancer 1997; 80 :1507-12

Meyers PA, Gorlick R.. Osteosarcoma. Pediatr Clin North Am. 1997; 44 :973-89

Hwang ES, Gerald W, Wollner N, Meyers P, La Quaglia MP.. Leiomyosarcoma in childhood and adolescence.. Ann Surg Oncol 1997; 4 :223-7

O’Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C.. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network.. Oncology 1996; 10 :1799-806

Terek RM, Brien EW, Marcove RC, Meyers PA, Lane JM, Healey JH.. Treatment of femoral Ewing sarcoma. Cancer 1996; 78 :70-8

Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL.. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.. J Clin Oncol 1996; 14 :1526-31

Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al.. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing sarcoma, in children and young adults. J Clin Oncol 1995; 13 :2796-804

Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M.. Osteogenic sarcoma with clinically detectable metastasis at initial presentation.. J Clin Oncol 1993; 11 :449-53

Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al.. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.. N Engl J Med 1992; 326 :1301-8

Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G.. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan Kettering experience. J Clin Oncol 1992; 10 :5-15

 

Publications on PubMed

Visit PubMed for a full listing of Dr. Meyers’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed